Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zai Lab LtdZLAB · Entity 4271 | Director · Chairperson & CEO | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zai Lab Ltd
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 1,221,401 |
Last balance in matching sequence
After 2026-07-02 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-07-01 · Exercise / conversion · Acquired 18,000 · Balance 1,221,784 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: ADSs acquired upon vesting of Restricted Share Units ("RSUs"). F3: Each RSU represents a contingent right to receive one ADS. Row 2 · 2026-07-01 · Tax withholding · Disposed 7,083 · Balance 1,214,701 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F4: These ADSs were withheld to cover taxes upon vesting of RSUs. Row 3 · 2026-07-02 · Exercise / conversion · Acquired 11,048 · Balance 1,225,749 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: ADSs acquired upon vesting of Restricted Share Units ("RSUs"). F3: Each RSU represents a contingent right to receive one ADS. Row 4 · 2026-07-02 · Tax withholding · Disposed 4,348 · Balance 1,221,401 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F4: These ADSs were withheld to cover taxes upon vesting of RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 36,000 |
Reported balance
After 2026-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-01 · Exercise / conversion · Disposed 18,000 · Balance 36,000 F3: Each RSU represents a contingent right to receive one ADS. F5: The RSUs vest in equal annual installments over four years beginning on 07/01/2025, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 33,146 |
Reported balance
After 2026-07-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-02 · Exercise / conversion · Disposed 11,048 · Balance 33,146 F3: Each RSU represents a contingent right to receive one ADS. F6: The RSUs vest in equal annual installments over four years beginning on 07/02/2026, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 80,393 |
Reported balance
After 2026-07-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-02 · Grant · Acquired 80,393 · Balance 80,393 F3: Each RSU represents a contingent right to receive one ADS. F7: The RSUs vest in equal annual installments over four years beginning on 07/02/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: ADSs acquired upon vesting of Restricted Share Units ("RSUs").
F3: Each RSU represents a contingent right to receive one ADS.
F4: These ADSs were withheld to cover taxes upon vesting of RSUs.
F5: The RSUs vest in equal annual installments over four years beginning on 07/01/2025, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
F6: The RSUs vest in equal annual installments over four years beginning on 07/02/2026, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
F7: The RSUs vest in equal annual installments over four years beginning on 07/02/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2021 Filed Sep 9, 2021 00:48 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,776 | $150.05 | $566,588.80 |
DisclosureSEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 5 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032,384 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: Reflects a weighted average sale price of $150.05 per share, at prices ranging from $149.57 to $150.53 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 00:48 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 649 | $148.97 | $96,681.53 |
DisclosureSEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 4 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,160 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: Reflects a weighted average sale price of $148.97 per share, at prices ranging from $148.52 to $149.37 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 00:48 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 86 | $147.90 | $12,719.40 |
DisclosureSEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 3 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,809 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $147.90 per share, at prices ranging from $147.50 to $148.04 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 00:48 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,161 | $146.73 | $170,353.53 |
DisclosureSEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 2 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,895 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $146.73 per share, at prices ranging from $146.41 to $147.32 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 00:48 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 382 | $143.25 | $54,721.50 |
DisclosureSEC source: 0001567619-21-016869 · doc1.xml · nonDerivative · entry 1 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,056 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,248 | $146.55 | $182,894.40 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 16 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,438 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F16 · price: Reflects a weighted average sale price of $146.55 per share, at prices ranging from $146.39 to $146.79 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 9,441 | $145.70 | $1,375,553.70 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 15 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,039,686 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F15 · price: Reflects a weighted average sale price of $145.70 per share, at prices ranging from $145.38 to $146.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 7,373 | $144.84 | $1,067,905.32 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 14 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049,127 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F14 · price: Reflects a weighted average sale price of $144.84 per share, at prices ranging from $144.37 to $145.37 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 6,083 | $143.94 | $875,587.02 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 13 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,056,500 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F13 · price: Reflects a weighted average sale price of $143.94 per share, at prices ranging from $143.32 to $144.31 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,057 | $147.75 | $156,171.75 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 12 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,583 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F12 · price: Reflects a weighted average sale price of $147.75 per share, at prices ranging from $147.27 to $148.27 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 8,571 | $146.35 | $1,254,365.85 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 11 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,640 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F11 · price: Reflects a weighted average sale price of $146.35 per share, at prices ranging from $146.18 to $147.11 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 11,859 | $145.85 | $1,729,635.15 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 10 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,072,211 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F10 · price: Reflects a weighted average sale price of $145.85 per share, at prices ranging from $145.17 to $146.17 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 7,251 | $144.73 | $1,049,437.23 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 9 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,084,070 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F9 · price: Reflects a weighted average sale price of $144.73 per share, at prices ranging from $144.15 to $145.15 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 111,111 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · derivative · entry 17 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,165 Underlying: Ordinary Shares · 111,111 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F17 · derivative.exercise_date: The Stock Options fully vested as of October 22, 2020. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 176 | $149.63 | $26,334.88 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 8 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,091,321 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F8 · price: Reflects a weighted average sale price of $149.63 per share, at prices ranging from $149.58 to $149.63 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,769 | $148.77 | $560,714.13 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 7 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,091,497 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F7 · price: Reflects a weighted average sale price of $148.77 per share, at prices ranging from $148.35 to $149.22 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 6,933 | $147.63 | $1,023,518.79 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 6 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,266 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F6 · price: Reflects a weighted average sale price of $147.63 per share, at prices ranging from $147.28 to $148.15 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 6,826 | $146.96 | $1,003,148.96 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 5 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,199 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F5 · price: Reflects a weighted average sale price of $146.96 per share, at prices ranging from $146.27 to $147.27 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,882 | $145.92 | $274,621.44 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 4 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,109,025 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F4 · price: Reflects a weighted average sale price of $145.92 per share, at prices ranging from $145.24 to $146.24 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,691 | $144.62 | $678,412.42 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 3 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,110,907 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F3 · price: Reflects a weighted average sale price of $144.62 per share, at prices ranging from $144.09 to $145.01 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,166 | $143.77 | $598,945.82 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 2 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,115,598 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F2 · price: Reflects a weighted average sale price of $143.77 per share, at prices ranging from $143.07 to $144.07 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 22:43 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 111,111 | $0.60 | $66,666.60 |
DisclosureSEC source: 0001567619-21-016760 · doc1.xml · nonDerivative · entry 1 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 50 | $148.24 | $7,412.00 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 15 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,653 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 5,126 | $147.64 | $756,802.64 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 14 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,703 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F14 · price: Reflects a weighted average sale price of $147.64 per share, at prices ranging from $147.23 to $148.20 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 12,963 | $146.68 | $1,901,412.84 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 13 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013,829 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F13 · price: Reflects a weighted average sale price of $146.68 per share, at prices ranging from $146.22 to $147.22 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 5,338 | $145.75 | $778,013.50 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 12 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,792 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F12 · price: Reflects a weighted average sale price of $145.75 per share, at prices ranging from $145.18 to $146.17 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,396 | $144.71 | $202,015.16 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 11 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032,130 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F11 · price: Reflects a weighted average sale price of $144.71 per share, at prices ranging from $144.09 to $145.07 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 963 | $143.39 | $138,084.57 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 10 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,526 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F10 · price: Reflects a weighted average sale price of $143.39 per share, at prices ranging from $143.06 to $143.90 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 381 | $141.78 | $54,018.18 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 9 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,489 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F9 · price: Reflects a weighted average sale price of $141.78 per share, at prices ranging from $141.39 to $142.18 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 111,111 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · derivative · entry 16 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,276 Underlying: Ordinary Shares · 111,111 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F15 · derivative.exercise_date: The Stock Options fully vested as of October 22, 2020. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,072 | $145.83 | $447,989.76 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 8 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116,649 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F8 · price: Reflects a weighted average sale price of $145.83 per share, at prices ranging from $145.73 to $146.03 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 60,405 | $145.14 | $8,767,181.70 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 7 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,870 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F7 · price: Reflects a weighted average sale price of $145.14 per share, at prices ranging from $144.70 to $145.69 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 10,183 | $144.09 | $1,467,268.47 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 6 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,942 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F6 · price: Reflects a weighted average sale price of $144.09 per share, at prices ranging from $143.69 to $144.69 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,043 | $143.30 | $579,361.90 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 5 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098,347 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: Reflects a weighted average sale price of $143.30 per share, at prices ranging from $142.66 to $143.65 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,025 | $141.73 | $287,003.25 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 4 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108,530 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: Reflects a weighted average sale price of $141.73 per share, at prices ranging from $141.33 to $142.30 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,051 | $140.68 | $288,534.68 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 3 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,573 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $140.68 per share, at prices ranging from $140.29 to $141.29 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,115 | $139.62 | $434,916.30 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 2 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114,598 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $139.62 per share, at prices ranging from $139.19 to $140.18 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 111,111 | $0.60 | $66,666.60 |
DisclosureSEC source: 0001567619-21-014370 · doc1.xml · nonDerivative · entry 1 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| July 02, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 483 | $177.84 | $85,896.72 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 11 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,653 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F11 · balance_after: Reflects a weighted average sale price of $177.84 per share, at prices ranging from $177.74 to $178.03 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 527 | $176.76 | $93,152.52 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 10 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,136 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F10 · balance_after: Reflects a weighted average sale price of $176.76 per share, at prices ranging from $176.40 to $177.17 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 11,849 | $175.55 | $2,080,091.95 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 9 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,663 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F9 · balance_after: Reflects a weighted average sale price of $175.55 per share, at prices ranging from $175.36 to $176.31 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 14,394 | $174.97 | $2,518,518.18 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 8 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,512 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F8 · balance_after: Reflects a weighted average sale price of $174.97 per share, at prices ranging from $174.36 to $175.35 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 111,111 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · derivative · entry 12 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,387 Underlying: Ordinary Shares · 111,111 shares Expires 2025-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F12 · derivative.exercise_date: The Stock Options fully vested as of October 22, 2020. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 865 | $178.83 | $154,687.95 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 7 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,906 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F7 · balance_after: Reflects a weighted average sale price of $178.83 per share, at prices ranging from $178.80 to $178.89 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 21,877 | $178.22 | $3,898,918.94 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 6 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,771 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F6 · balance_after: Reflects a weighted average sale price of $178.22 per share, at prices ranging from $177.79 to $178.79 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 8,758 | $177.14 | $1,551,392.12 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 5 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,648 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · balance_after: Reflects a weighted average sale price of $177.14 per share, at prices ranging from $176.76 to $177.71 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,411 | $176.04 | $776,512.44 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 4 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067,406 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · balance_after: Reflects a weighted average sale price of $176.04 per share, at prices ranging from $175.70 to $176.63 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 6,670 | $175.16 | $1,168,317.20 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 3 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,071,817 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · balance_after: Reflects a weighted average sale price of $175.16 per share, at prices ranging from $174.70 to $175.68 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 41,277 | $174.05 | $7,184,261.85 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 2 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,078,487 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Reflects a weighted average sale price of $174.05 per share, at prices ranging from $173.68 to $174.60 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 111,111 | $0.60 | $66,666.60 |
DisclosureSEC source: 0001567619-21-012954 · doc1.xml · nonDerivative · entry 1 Du Ying · CIK 0001731790 · Director · Chairwoman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 3, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.